Five PubMed papers for July 28–August 4: weekly HIV therapy leads the window

Five records entered PubMed during the July 28–August 4, 2026 date window. The lead is a phase 3 trial of once-weekly oral islatravir–lenacapavir for people with virologically suppressed HIV-1: at week 48, it was noninferior to continuing daily bictegravir/emtricitabine/tenofovir alafenamide. The other four cover pulmonary arterial hypertension, postoperative acute kidney injury, Long COVID care pathways, and antihistamines for atopic dermatitis. 1

These papers are too new for citation counts to be a stable leaderboard. OpenAlex showed cited-by counts of 0, 0, 1, 0, and 0 in the order below on August 4. I therefore used early citation signal as one input, then broke ties with journal impact tier, study design, primary-endpoint strength, and immediate clinical or research utility. The tier labels are editorial categories, not current Journal Citation Reports values. 23456

Journal / indexing: New England Journal of Medicine; PubMed entry date July 29, 2026; top-tier general medicine. 7

Design and population: This was a phase 3, double-blind, randomized, active-controlled noninferiority trial. It enrolled 607 adults with suppressed HIV-1 who were already receiving daily bictegravir/emtricitabine/tenofovir alafenamide and randomized them to switch to once-weekly oral islatravir–lenacapavir or continue daily therapy. 7

Primary result: At week 48, HIV-1 RNA of at least 50 copies/mL occurred in 0% with weekly therapy versus 0.3% with daily therapy. The between-group difference was -0.3 percentage points, with a 95.002% confidence interval of -1.4 to 0.8, meeting the prespecified noninferiority criterion. HIV-1 RNA below 50 copies/mL was present in 93.4% and 92.4%, respectively. CD4 counts changed by similar amounts; the between-group difference was 12 cells/µL (95% CI -16 to 39). 7

Evidence and limitation: The randomized, double-blind phase 3 design gives the virologic comparison a strong evidentiary base. The population was a switch population with already suppressed virus, not people starting treatment with high viral loads or active adherence problems. The primary readout also covers 48 weeks, so durability, resistance management, drug interactions, and the practical effect of a weekly regimen need longer follow-up. Adverse-event discontinuation was 2.0% with weekly therapy and 1.7% with daily therapy; serious adverse events were 5.3% and 4.6%. 7

Clinical / research implication: For a suppressed patient who wants fewer dosing days, the result makes a weekly oral option clinically plausible. It does not yet establish that weekly treatment is easier to adhere to, safer over years, or interchangeable across all HIV populations.

Author / funding: First author Jürgen K. Rockstroh is affiliated with University Hospital Bonn. The trial was funded by Gilead Sciences and Merck Sharp & Dohme. 7

Open the original: PubMed record · NEJM article

Journal / indexing: The Lancet; PubMed entry date July 28, 2026; top-tier general medicine. 8

Design and population: ADVANCE OUTCOMES was a randomized, double-blind, placebo-controlled, event-driven phase 3 trial. Of 728 patients who were randomized and treated, 687 entered the efficacy and safety analyses after 41 participants from Chinese sites were excluded because of regulatory challenges and data-integrity concerns. The analyzed groups were 350 receiving ralinepag and 337 receiving placebo; 80% were already on dual background pulmonary arterial hypertension therapy. 8

Primary result: A first clinical-worsening event occurred in 18% with ralinepag versus 36% with placebo. The hazard ratio was 0.45 (95% CI 0.33–0.62; P<0.0001). The composite included death, hospitalization for worsening PAH or right-heart failure, escalation to parenteral or inhaled prostacyclin therapy, disease progression, and unsatisfactory long-term response. 8

Evidence and limitation: The event-driven phase 3 design and contemporary background therapy make the result clinically legible. The exclusion of 41 treated participants is not a footnote to ignore: it narrows confidence about how the result generalizes to all trial sites. Ralinepag also produced more adverse-event-related discontinuations, 19% versus 3%, although serious adverse events were similar at 28% versus 31% and deaths attributed to adverse events were 4% in each group. 8

Clinical / research implication: The efficacy signal supports adding an oral prostacyclin-pathway option for patients with PAH who remain at risk despite background therapy. The discontinuation gap means the treatment's place will depend on whether clinicians can preserve the event reduction without losing patients to tolerability.

Author / funding: First author Vallerie V. McLaughlin is affiliated with the University of Michigan Medical School. The study was funded by United Therapeutics Corporation. 8

Open the original: PubMed record · The Lancet article

Journal / indexing: JAMA; PubMed entry date July 30, 2026; top-tier general medicine. 9

Design and population: This was a multicenter, double-blind, placebo-controlled randomized clinical trial in the Netherlands. The 784 enrolled adults received dapagliflozin or placebo from the day before cardiac surgery through postoperative day 2; 778 completed follow-up. The primary outcome was acute kidney injury within 7 days of surgery, assessed using Kidney Disease: Improving Global Outcomes criteria. 9

Primary result: AKI occurred in 28% of the dapagliflozin group versus 52% of the placebo group (risk ratio 0.54; 95% CI 0.45–0.65; P<0.001). The treatment did not change postoperative atrial fibrillation, which occurred in 45% of both groups, or reoperation, which occurred in 11% versus 10%. 9

Evidence and limitation: Randomization, blinding, and a clinically defined postoperative outcome strengthen the signal. The trial tested a short four-dose perioperative regimen in seven Dutch hospitals, so it does not answer whether the result holds across health systems, surgical mixes, or patients with different baseline kidney risk. The abstract also does not report a study-funding statement; that absence is preferable to inferring a sponsor from the drug name. 9

Clinical / research implication: A large reduction in early AKI is a strong reason to read the full safety tables and protocol before changing perioperative practice. The result is promising, but one short-course trial does not establish the best timing, patient selection, or interaction with standard fasting and volume-management protocols.

Author / funding: First author Maartina J. P. Oosterom-Eijmael is affiliated with Amsterdam University Medical Center. The PubMed record does not state a study-funding source in the abstract; it lists outside-work grant disclosures. 9

Open the original: PubMed record · JAMA article

Journal / indexing: Nature Medicine; PubMed entry date July 28, 2026; top-tier specialty medicine. 10

Design and population: This phase 3, multicenter, cluster-randomized trial ran through six NHS Long COVID clinics in England. Primary care networks were assigned to multi-organ MRI, digital rehabilitation, both interventions, or neither intervention as usual care. The study included 122 clusters and 1,152 consenting participants; baseline fatigue scores were balanced, with a mean Fatigue Assessment Scale score of 35.8. 10

Primary result: Fatigue improved across all arms by 4.5 points to a mean of 31.3 at 12 weeks. Compared with usual care, the 12-week FAS differences were -0.18 for multi-organ MRI (95% CI -0.72 to 1.09; P=0.69), -0.53 for digital rehabilitation (-1.42 to 0.36; P=0.25), and -0.17 for their interaction (-1.06 to 0.72; P=0.71). No serious adverse events were related to the interventions. 10

Evidence and limitation: Cluster randomization and a large NHS multicenter sample test implementation in a real service environment. The main result is also easy to overread: improvement in every arm does not show that MRI or digital rehabilitation caused the improvement, and none of the between-arm estimates was statistically persuasive at 12 weeks. The study itself leaves longer-term rehabilitation effects and the optimal integrated pathway open for further trials.

Clinical / research implication: The result argues against assuming that adding a costly diagnostic scan or digital program automatically improves short-term fatigue beyond multidisciplinary care. It supports evaluating which components help particular subgroups over longer follow-up rather than treating the pathway as a single package.

Author / funding: The paper is authored by the STIMULATE-ICP Consortium rather than a single lead author in the PubMed author field. Funding came through the UK National Institute for Health and Care Research, grant COV-LT2-0043. 10

Open the original: PubMed record · Nature Medicine article

Journal / indexing: BMJ; PubMed entry date July 29, 2026; top-tier general medicine. 11

Design and population: This systematic review and network meta-analysis synthesized 47 randomized trials involving 6,230 adults and children with atopic dermatitis. It assessed oral H1 antihistamines as add-on therapy against placebo or other options, with eczema severity, itch, sleep, flares, and cognitive impairment among the outcomes. 11

Primary result: Compared with placebo, H1 antihistamines produced a mean eczema-severity difference of -1.87 points (95% credible interval -3.47 to -0.27) and a mean itch difference of -0.89 (-1.41 to -0.37). Both effects were smaller than the review's minimal important differences of 8.2 points for severity and 3 points for itch. First-generation agents were also likely to increase cognitive impairment; evidence for sleep and exacerbations was lower certainty. 11

Evidence and limitation: The review's breadth and explicit minimal-important-difference threshold make it more useful than a simple count of statistically positive trials. Network estimates still inherit the limitations of the underlying studies, and the result concerns routine add-on oral antihistamines; it does not address every indication for which a clinician might use one, such as a separately diagnosed allergic condition.

Clinical / research implication: The average effect does not support routine antihistamines as an eczema-severity or itch treatment. If an antihistamine is used for a specific comorbidity or sleep problem, the choice should be separated from the assumption that it controls the dermatitis itself, especially when cognitive effects matter.

Author / funding: First author Alexandro W. L. Chu is affiliated with McMaster University and the University of Toronto. The authors report support from the American Academy of Allergy, Asthma and Immunology and the American College of Allergy, Asthma and Immunology Joint Task Force for the submitted work, plus outside-work support from the US National Institute of Allergy and Infectious Diseases. 11

Open the original: PubMed record · BMJ article

Open the first paper if the burden of daily HIV dosing is clinically relevant to your patients or trial program; the virologic noninferiority result is the week's clearest change in treatment format. Read the ralinepag paper if PAH escalation decisions are in scope, but read the discontinuation data with the hazard ratio. The dapagliflozin trial is the most immediately practice-facing perioperative signal, while STIMULATE-ICP is useful precisely because it narrows what added Long COVID infrastructure can be expected to do. The BMJ review is the quickest read for clinicians deciding whether oral antihistamines deserve a routine place in atopic dermatitis care.